Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dapagliflozin Tab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dapagliflozin 10mg | ACTIVE_COMPARATOR | Active arm will be 6 weeks in duration, separated by a 2-week wash-out period. |
| Placebo | PLACEBO_COMPARATOR | Placebo arm will be 6 weeks in duration, separated by a 2-week wash-out period. |
| Name | Type | Description |
|---|---|---|
| Dapagliflozin 10Mg Tab | DRUG | This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo. |
| Placebo | DRUG | This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo. |
Inclusion Criteria: 1. Diagnosis of HFrEF with NYHA Class II-III functional class, which has been present for at least two months 2. Left ventricular ejection fraction ≤ 40% 3. Stable medical therapy for at least 1 month 4. Plasma NT-proBNP level of: ≥ 200pg/mL; OR ≥ 125pg/mL if they were hospitali...
Dapagliflozin Tab is a small molecule being studied for the treatment of heart failure with reduced ejection fraction (HFrEF). It is currently in Phase 2 clinical development. The drug is being developed by Amgen Inc. (NASDAQ: AMGN).
Dapagliflozin Tab is a small molecule. The specific molecular target for Dapagliflozin Tab has not been disclosed in the available information. It is being investigated for its effects on submaximal exercise tolerance in patients with heart failure with reduced ejection fraction (HFrEF).
Dapagliflozin Tab is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 2 clinical development for heart failure with reduced ejection fraction (HFrEF).
Dapagliflozin Tab is in Phase 2 clinical development. It is an investigational drug being studied for heart failure with reduced ejection fraction (HFrEF). It has not been approved by regulatory authorities and remains in clinical trials.
Dapagliflozin Tab has one completed Phase 2 clinical trial, identified as NCT04956809, titled "Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure." The trial enrolled 3 participants in the United States and was a randomized, double-blind, placebo-controlled study.
Dapagliflozin Tab is a formulation of dapagliflozin, a small molecule drug. It is being developed by Amgen Inc. for heart failure with reduced ejection fraction (HFrEF). The drug is currently in Phase 2 clinical development and is not yet approved.